|
Hydatidiform Mole, Partial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that the use of p57 and Ki-67 IHC cannot reliably distinguish PM from NMAs.
|
30394942 |
2020 |
|
Complete hydatidiform mole
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All CM cases showed absent (<10%) p57 IHC in chorionic villi.
|
30394942 |
2020 |
|
Hydatidiform Mole
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Five cases of complete HM, diploid with 2 paternal genome sets (CHM;PP), 5 cases of partial HM, triploid with 2 paternal and 1 maternal genome sets (PHM;PPM), and 5 cases of non-HM, with diploid biparental genomes (non-HM;PM) were stained with p57 Abs: 57P06, EP183, KP10, and KP39.
|
31567274 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Increased Ki67, SF-1 and IGF2 immunostaining also correlated with worse survival. p57 was more specific in determining benign status of a tumor.
|
30686519 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although cyclin D1 and p57 expression did not affect survival rates in RCC patients, proper validation and establishment of the qualitative cut-off point are needed for these tumors.
|
30941985 |
2019 |
|
Complete hydatidiform mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abnormal chorionic villi were seen in all cases with histomorphological and/or p57 immunohistochemical features simulating either partial or complete mole.
|
30952972 |
2019 |
|
Complete hydatidiform mole
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We compared the allele zygosity ratio in 11 nonmolar donor egg POC, 5 dispermic (heterozygous) CHM and 31 monospermic (homozygous) CHM, without knowledge of the use of a donor egg, the histologic findings, or results of p57 immunohistochemical staining.
|
28463912 |
2018 |
|
Hydatidiform Mole
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Analyses of p57 expression by immunohistochemistry and polymerase chain reaction-based DNA genotyping have emerged as powerful diagnostic methods for accurate classification of hydatidiform moles.
|
28135560 |
2017 |
|
Hydatidiform Mole, Partial
|
0.100 |
Biomarker
|
disease |
BEFREE |
IHC with p57 was negative in 96 per cent CM and positive in 100 and 95 per cent PM and non-molar controls, respectively.
|
28574027 |
2017 |
|
Complete hydatidiform mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry p57 demonstrated negative staining in the villous stromal and cytotrophoblastic cells, supporting the diagnosis of CHM.
|
28800576 |
2017 |
|
Complete hydatidiform mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detailed histomorphological review along with p57 IHC was carried out in 28 diagnosed cases (23 CM, 4 PM and 1 molar pregnancy not categorized) and 25 controls of four normal placentas and 21 POC (8 non-hydropic and 13 HA).
|
28574027 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Immunohistochemical analysis revealed nuclear loss of p57 staining consistent with loss of the maternal 11p15 allele in 11 of the 12 insulinomas, including all five MEN1-associated tumors.
|
26756113 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic and epigenetic alterations causing loss of p57 function are the most frequent cause of Beckwith-Wiedemann syndrome (BWS), a genetic disorder characterized by multiple developmental anomalies and increased susceptibility to tumour development during childhood.
|
27015986 |
2016 |
|
Complete hydatidiform mole
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a prospective series of 1024 products of conception specimens subjected to immunohistochemical analysis of p57 expression and molecular genotyping with short tandem-repeat markers, 288 CHMs were diagnosed, of which 126 were genotyped, including 16 invasive CHMs.
|
26535984 |
2016 |
|
Hydatidiform Mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
A pilot Placental Molar Diagnostic (PMD) Service was established combining histopathology, p57 immunohistochemistry, and molecular genotyping analysis for both in-house and referred-in cases suspicious for HM or with a preliminary diagnosis of HM.
|
25851707 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Co-expression of p57 and p-cofilin was reduced in specimens from patients with tumors at later stages (III + IV), tumors showing capsular invasion and metastatic tumors.
|
26271467 |
2015 |
|
Hydatidiform Mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
Characteristics of hydatidiform moles: analysis of a prospective series with p57 immunohistochemistry and molecular genotyping.
|
23887308 |
2014 |
|
Hydatidiform Mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, combined p57 immunostaining and FISH with a set of 3 CEP probes for chromosomes X, Y, and 17 could be useful in the classification of hydatidiform moles.
|
24613849 |
2014 |
|
Complete hydatidiform mole
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Of the 14 androgenetic/biparental mosaics with discordant p57 expression, 6 were uniformly mosaic and 8 had a p57-negative androgenetic molar component. p57 expression is highly correlated with genotyping, serves as a reliable marker for diagnosis of complete hydatidiform moles, and identifies androgenetic cell lines in mosaic conceptions.
|
23887308 |
2014 |
|
Hydatidiform Mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have demonstrated the value of ancillary techniques, including p57 immunohistochemistry and short tandem repeat genotyping, for distinguishing hydatidiform moles (HM) from nonmolar specimens and for subtyping HMs as complete hydatidiform moles (CHM) and partial hydatidiform moles (PHM).
|
23370656 |
2013 |
|
Hydatidiform Mole
|
0.100 |
Biomarker
|
disease |
BEFREE |
When pathologists encounter patients with molar pregnancies that are diploid and p57 negative and yet have fetal elements such as nucleated red blood cells or immature fetal tissues, it should heighten their suspicion of a possible genetic basis and appropriate molecular genetic workup performed with counseling offered.
|
23722513 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Loss of p57 expression was associated with HCC with higher α-fetoprotein (AFP) levels (>400 ng/ml; P=0.044), larger tumor size (>5 cm, P=0.004), poor tumor differentiation (P=0.020), advanced TNM stage (P=0.027), capsule invasion (P=0.018) and tumor thrombosis (P=0.008), whereas expression of RhoA protein was significantly associated with poor tumor differentiation (P=0.042), capsule invasion (P=0.022), and tumor thrombosis (P=0.002).
|
23842948 |
2013 |
|
Hydatidiform Mole, Partial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have demonstrated the value of ancillary techniques, including p57 immunohistochemistry and short tandem repeat genotyping, for distinguishing hydatidiform moles (HM) from nonmolar specimens and for subtyping HMs as complete hydatidiform moles (CHM) and partial hydatidiform moles (PHM).
|
23370656 |
2013 |
|
Complete hydatidiform mole
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recognition of their distinctive p57 expression patterns and genotyping results can prevent misclassification as typical CHMs, PHMs, or nonmolar specimens.
|
23370656 |
2013 |
|
Hydatidiform Mole
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we describe a first trimester abortus with morphologic features consistent with a hydatidiform mole and p57 expression pattern supporting a diagnosis of PHM.
|
22123726 |
2012 |